Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsParkland Biosimilar Coverage Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentParkland Community Health PlanPolicy N/A

    Clinical Policy: Biosimilar-First Coverage for Clinician-Administered Drugs

    Customize your policy alerts

    Sign up for all parklandcommunityhealthplan policy alerts

    Know when parklandcommunityhealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Establishes biosimilar-first utilization management and billing requirements for clinician-administered drugs covered under the medical benefit for STAR and CHIP members in Texas.

    Policy Summary
    PayerParkland Community Health Plan
    PolicyBiosimilar-First Coverage for Clinician-Administered Drugs
    Policy CodePolicy N/A
    Change TypeCurrent policy
    Effective DateJun 6, 2026
    Next Review DateN/A
    Key ActionUse the PCHP-designated preferred biosimilar first when one is available; obtain prior authorization for a reference product or non-preferred biosimilar.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Biosimilar-first
    Utilization management strategy
    STAR/CHIPLines of business
    4Coverage requirements
    PA requiredProduct restriction
    7Product groups addressed

    Coverage Requirements

    Coverage Requirements

    Coverage requires ALL of the following:

    Coverage requirements

    • The biosimilar product is approved by the U.S. Food and Drug Administration (FDA) for the requested indication.
    • The requested use is consistent with FDA-approved labeling or supported by nationally recognized clinical guidelines or compendia when applicable.
    • The use meets applicable medical necessity criteria.
    • Coverage complies with Texas Medicaid and other applicable regulatory requirements, including the NDC-HCPCS crosswalk benefit.

    Preferred Biosimilar Utilization

    When a biosimilar is available for a reference product, ALL of the following apply:

    Preferred biosimilar utilization

    • Use the PCHP-designated preferred biosimilar product before approval of the reference product or another non-preferred biosimilar.
    • If requesting the reference product or a non-preferred biosimilar, submit clinical justification and obtain prior authorization.
    • The request satisfies prior authorization considerations, including clinical indication, site of care, prescribing provider specialty, step therapy requirements, and compliance with preferred-product policies.

    Continuity of Care

    A member stable on a reference product or biosimilar may be eligible for continued coverage when ALL of the following are met:

    Continuity of care

    • The treatment is medically necessary.
    • The member continues to respond well to the preferred maintenance therapy.
    • Transitioning to another product would present a clinical concern.

    Initial Biosimilar Authorization

    Initial Biosimilar Authorization

    Initial coverage requires ALL of the following:

    Initial biosimilar authorization

    • The biosimilar product is approved by the U.S. Food and Drug Administration (FDA) for the requested indication.
    • The requested use is consistent with FDA-approved labeling or supported by nationally recognized clinical guidelines or compendia when applicable.
    • The use meets applicable medical necessity criteria and Texas Medicaid and NDC-HCPCS crosswalk requirements.
    • The PCHP-designated preferred biosimilar is used before requesting a reference product or non-preferred biosimilar.

    Continuation of Therapy

    Continuity of Care

    A member stable on a reference product or biosimilar may be eligible for continued coverage when ALL of the following are met:

    Stable therapy continuation

    • The treatment remains medically necessary.
    • The member continues to respond well to the preferred maintenance therapy.
    • Transitioning to another product would present a clinical concern.

    Preferred Product Sequence

    StepRequirementAuthorization
    1Use the PCHP-designated preferred biosimilar first when one is available.Reference products or non-preferred biosimilars require clinical justification and prior authorization before approval.

    Biosimilar Coding and Dosing

    Biosimilars and HCPCS codes — Actemra, Avastin, and Neupogen groupsHCPCS
    J3262Actemra® — Tocilizumab
    Q5135Tyenne — Tocilizumab-aazg
    Q5133Tofidence — Tocilizumab-bavi
    Q5156Avtozma — Tocilizumab-anoh
    J9035Avastin® — Bevacizumab
    Q5118Zirabev — Bevacizumab-bvzr
    Q5107Mvasi — Bevacizumab-awwb
    Q5129Vegzelma — Bevacizumab-adcd
    Q5126Alymsys — Bevacizumab-maly
    J4112Neupogen® — Filgrastim
    1–10 of 12
    1/2
    Biosimilars and HCPCS codes — Releuko, Remicade, Rituxan, Soliris, and Stelara groupsHCPCS
    Q5125Releuko — Filgrastim-ayow
    J1745Remicade® — Infliximab
    Q5103Inflectra — Infliximab-dyyb
    Q5121Avsola — Infliximab-axxq
    Q5104Renflexis — Infliximab-abda
    J9312Rituxan® — Rituximab
    Q5119Ruxience — Rituximab-pvvr
    Q5123Riabni — Rituximab-arrx
    J1299Soliris® — Eculizumab
    Q5151Epysqli — Eculizumab-aagh
    1–10 of 17
    1/2
    Polyarticular Juvenile Idiopathic Arthritis — Tocilizumab
    Weight below 30 kg10 mg/kg intravenously every 4 weeks
    Weight 30 kg or greater8 mg/kg intravenously every 4 weeks
    Maximum dose10 mg/kg intravenously every 4 weeks
    Rheumatoid Arthritis — Tocilizumab
    Initial regimen4 mg/kg intravenously every 4 weeks
    Response-based escalationIncrease to 8 mg/kg intravenously every 4 weeks based on clinical response
    Maximum dose

    Authorization and Billing Requirements

    Prior Authorization

    Biosimilar Prior Authorization Factors

    Prior authorization requirements for a biosimilar may vary based on the clinical indication, site of care, prescribing provider specialty, step therapy requirements, and compliance with preferred product policies.

    • Clinical indication
    • Site of care
    • Prescribing provider specialty
    • Step therapy requirements
    • Preferred product policy compliance
    Step Therapy

    Use the Preferred Biosimilar First

    When a biosimilar is available for a reference product, coverage requires use of the preferred biosimilar before approval of the reference product or another non-preferred biosimilar.

    • PCHP may designate one or more preferred biosimilars.

    Policy Background

    A biosimilar is an FDA-approved biologic that is highly similar to its reference product, with no clinically meaningful differences in safety, purity, or potency. PCHP applies a biosimilar-first utilization management strategy to clinician-administered drugs provided under the medical benefit and reimbursed through the NDC-HCPCS crosswalk. When available, a PCHP-designated preferred biosimilar is used before the reference product or another non-preferred biosimilar; exceptions may be considered when clinical justification supports prior authorization. This approach promotes clinically appropriate utilization, supports cost-effective care, and maintains compliance with applicable federal and Texas requirements.

    Key Definitions

    Biosimilar
    FDA statusA biologic product approved by the FDA
    Similarity to reference productHighly similar to a reference product
    Clinical differencesHas no clinically meaningful differences in safety, purity, or potency
    NDC-HCPCS Crosswalk
    PurposeBilling framework for reimbursement under the medical benefit
    NDC componentLinks National Drug Codes (NDCs)
    HCPCS componentLinks HCPCS codes to the applicable National Drug Codes

    Administration Setting

    Note

    Use the appropriate infusion setting and route

    Administer the listed regimens primarily by intravenous infusion in an infusion center. Subcutaneous administration is specified for selected filgrastim and ustekinumab products; confirm the product-specific route and regimen before administration.

    Preferred Biosimilar Designation

    Billing Rule

    Sequence the preferred biosimilar before the reference product

    When a biosimilar is available for an applicable FDA-approved reference product, PCHP may designate one or more preferred biosimilars. The preferred biosimilar is required before approval of the reference product or another non-preferred biosimilar, subject to clinical justification and prior authorization.

    Policy Summary
    PayerParkland Community Health Plan
    PolicyBiosimilar-First Coverage for Clinician-Administered Drugs
    Policy CodePolicy N/A
    Change TypeCurrent policy
    Effective DateJun 6, 2026
    Next Review DateN/A
    Key ActionUse the PCHP-designated preferred biosimilar first when one is available; obtain prior authorization for a reference product or non-preferred biosimilar.
    SourceLink
    On This Page
    Coverage RequirementsInitial Biosimilar AuthorizationContinuation of TherapyPreferred Product SequenceBiosimilar Coding and DosingAuthorization and Billing RequirementsPolicy BackgroundKey DefinitionsAdministration SettingPreferred Biosimilar Designation
    For a reference product or non-preferred biosimilar, clinical justification is submitted and prior authorization is obtained.
    800 mg intravenously every 4 weeks
    Cytokine Release Syndrome — Tocilizumab
    Weight below 30 kg12 mg/kg intravenously per infusion
    Weight 30 kg or greater8 mg/kg intravenously per infusion
    Additional dosesIf there is no clinical improvement after the first dose, up to 3 additional doses may be given
    Maximum treatment800 mg per infusion, up to 4 doses
    Bevacizumab Oncology Dosing Examples
    Cervical cancer15 mg/kg intravenously every 3 weeks
    Colorectal cancer5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks
    Glioblastoma10 mg/kg intravenously
    Hepatocellular carcinoma15 mg/kg intravenously once
    Metastatic nonsquamous non-small-cell lung cancer15 mg/kg intravenously every 3 weeks
    Metastatic renal cell carcinoma10 mg/kg intravenously every 2 weeks
    Filgrastim Dosing
    Chemotherapy-induced neutropenia5 mcg/kg subcutaneously or intravenously daily
    ANC-based adjustmentThe dose may be increased in 5 mcg/kg increments for each chemotherapy cycle according to the duration and severity of the ANC
    Maximum intravenous dose30 mcg/kg/day
    Maximum subcutaneous dose24 mcg/kg/day
    Other listed regimensCongenital chronic neutropenia: 6 mcg/kg subcutaneously twice daily; idiopathic or cyclic chronic neutropenia: 5 mcg/kg subcutaneously daily; bone marrow transplant: 10 mcg/kg intravenously daily; peripheral blood progenitor cell mobilization: 10 mcg/kg subcutaneously daily as a bolus or continuous infusion
  1. Preferred-product requirements apply before requesting a reference product or non-preferred biosimilar.
  2. Unsupported block type: documentation

    Billing Rule

    Biosimilar Billing Documentation

    Medical-benefit claims for biosimilars must include complete coding and billing documentation and comply with PCHP coverage and authorization requirements.

    • Appropriate HCPCS code
    • National Drug Code (NDC)
    • Applicable modifiers
    • Documentation of PCHP coverage criteria and authorization requirements
    • Vendor Drug Program and Texas Medicaid billing guidance for biologics and biosimilars

    Unsupported block type: denial_risk

    Denial Risk

    Failure to Meet Coverage Requirements

    Coverage may be denied when the biosimilar is not FDA-approved for the requested indication, the use is inconsistent with FDA labeling or qualifying clinical support, medical necessity is not established, or regulatory and benefit requirements are not met.

    • FDA approval for the requested indication is required.
    • Use must be consistent with FDA-approved labeling or supported by nationally recognized clinical guidelines or compendia when applicable.
    • The requested use must meet applicable medical necessity criteria.
    • Coverage must comply with Texas Medicaid and other applicable regulatory requirements, including the NDC-HCPCS crosswalk benefit.
    Prior Authorization

    Prior Authorization Criteria Not Met

    Prior authorization determinations consider the requested indication, site of care, prescribing provider specialty, step therapy requirements, and compliance with preferred product policies.

    • Clinical indication
    • Site of care
    • Prescribing provider specialty
    • Step therapy requirements
    • Preferred product policy compliance